title: Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.
authors.forename: Ilyssa O
authors.initials: IO
authors.lastname: Gordon
authors.forename: Takisha
authors.initials: T
authors.lastname: Wade
authors.forename: Kevin
authors.initials: K
authors.lastname: Chin
authors.forename: Jerome
authors.initials: J
authors.lastname: Dickstein
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Gajewski
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology; D060908:CTLA-4 Antigen; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000628:therapy*; D008875:Middle Aged; D012010:Red-Cell Aplasia, Pure / Q000175:diagnosis* / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D000074324:Ipilimumab